FOXP3 and cancer: Likewise, monensin-mediated inhibition of Foxp3 iTreg development could, in part, explain the mechanisms underlying its effective re-purposing in the treatment of several different types of cancers (Deng et al., 2015) (Tumova et al., 2014).